Cohen Klingenstein LLC Cuts Stake in GSK plc (NYSE:GSK)

Cohen Klingenstein LLC cut its holdings in shares of GSK plc (NYSE:GSK) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 98,198 shares of the pharmaceutical company’s stock after selling 6,114 shares during the quarter. Cohen Klingenstein LLC’s holdings in GSK were worth $3,321,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Cypress Wealth Services LLC lifted its stake in GSK by 23.8% in the fourth quarter. Cypress Wealth Services LLC now owns 11,966 shares of the pharmaceutical company’s stock worth $405,000 after purchasing an additional 2,301 shares during the last quarter. Advisors Management Group Inc. ADV increased its holdings in shares of GSK by 6.1% in the fourth quarter. Advisors Management Group Inc. ADV now owns 91,530 shares of the pharmaceutical company’s stock worth $3,096,000 after buying an additional 5,259 shares during the period. San Luis Wealth Advisors LLC lifted its stake in shares of GSK by 37.8% in the 4th quarter. San Luis Wealth Advisors LLC now owns 21,968 shares of the pharmaceutical company’s stock valued at $743,000 after acquiring an additional 6,031 shares during the last quarter. Ignite Planners LLC boosted its holdings in GSK by 6.8% during the 4th quarter. Ignite Planners LLC now owns 18,965 shares of the pharmaceutical company’s stock valued at $635,000 after acquiring an additional 1,210 shares during the period. Finally, Marcum Wealth LLC grew its position in GSK by 6.7% during the 4th quarter. Marcum Wealth LLC now owns 9,366 shares of the pharmaceutical company’s stock worth $317,000 after acquiring an additional 591 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.0 %

Shares of GSK stock opened at $33.46 on Friday. The stock has a market capitalization of $69.34 billion, a PE ratio of 21.72, a P/E/G ratio of 1.44 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The company’s fifty day simple moving average is $34.08 and its 200-day simple moving average is $38.01. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were paid a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.70%. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 96.10%.

Analysts Set New Price Targets

Several brokerages have weighed in on GSK. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.